Trulicity Patent Protection
0 patents · Eli Lilly and Company
Biosimilar Pathway
Trulicity (dulaglutide) is a biologic, not a small-molecule drug. Biologics are not listed in the FDA Orange Book and do not face conventional “generic” competition. Instead, follow-on competitors called biosimilars can be approved through the FDA’s BPCIA pathway, typically after the reference product’s 12-year exclusivity period and the resolution of any patent litigation.
For the current biosimilar approvals and exclusivity status of Trulicity, see the authoritative FDA Purple Book listing for dulaglutide.
Related Drug Patent Expirations
8 patents · earliest expires 2036 · Eli Lilly and Company
0 patents · Eli Lilly and Company
1 patents · earliest expires 2031 · Eli Lilly and Company
0 patents · Genentech Inc.
9 patents · earliest expires 2033 · Gilead Sciences Inc.
0 patents · Novartis AG
The Trulicity record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how Trulicity sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for Trulicity’s peers within U.S. brand-name drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.